Evotec SE
NASDAQ:EVODrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $518.56M
- Beta
- 1.30
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$1.09
Volume 0.04M
Average 0.08M
EVO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Evotec SENASDAQ: EVO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization remains negative
Q1 FY2026 depreciation & amortization was €24.21M, compared with €0 a year earlier. Trailing-twelve-month depreciation & amortization was €73.11M. Over 3 fiscal years it compounded at +4.7% a year.
Context
- Depreciation & amortization amounted to 12.6% of revenue in FY2025, down 0.1 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly depreciation & amortization holds near €24.21M or moves back toward the trailing-twelve-month quarterly average of €18.28M.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
EUR · from the income statement
- Latest · FY2025
- 95.55M EUR
- Year-over-year change
- -6.0%
- 4-year CAGR
- +7.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 95.55M | -6.0% |
| FY2024 | 2024-12-31 | 101.62M | +9.3% |
| FY2023 | 2023-12-31 | 92.98M | +11.8% |
| FY2022 | 2022-12-31 | 83.2M | +18.2% |
| FY2021 | 2021-12-31 | 70.4M | — |
Depreciation & Amortization vs competitors
How EVO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +32.5% is the 2nd highest of 10, against a peer median of +6.2%.
- Depreciation & amortization amounts to 9.8% of revenue for EVO, versus a peer median of 7.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $233.19M USD | +6.2% | +20.0% | 9.3% | |
| LTM Feb 2026 | $113.28M USD | -37.8% | -2.0% | 9.6% | |
| LTM Mar 2026 | $91.19M USD | +11.8% | -0.2% | 12.4% | |
| LTM Mar 2026 | €73.11M EUR | +32.5% | +4.7% | 9.8% | |
| LTM Sep 2026 | $56.52M USD | -7.7% | — | 9.1% | |
| LTM Mar 2026 | $31.92M USD | -1.4% | +22.9% | 5.7% | |
| LTM Mar 2026 | $19.5M USD | +32.3% | +88.3% | 7.3% | |
| LTM Mar 2026 | $18M USD | +53.3% | +17.4% | 2.7% | |
| LTM Sep 2026 | $4.4M USD | -30.7% | +11.5% | 1.6% | |
| LTM Sep 2026 | €483K EUR | +19.4% | +39.9% | — | |
| LTM Sep 2026 | $0 USD | — | +72.0% | 0.0% | |
| Peer median (excluding EVO) | — | +6.2% | +20.0% | 7.3% | |
Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 618.03M | 751.45M | 781.43M | 796.97M | 757.26M |
| Cost of Revenue | 466.49M | 577.38M | 606.38M | 682.09M | 694.6M |
| Gross Profit | 151.54M | 174.07M | 175.05M | 114.88M | 62.66M |
| Gross Margin | 24.5% | 23.2% | 22.4% | 14.4% | 8.3% |
| Research & Development | 65.7M | 76.64M | 68.53M | 50.86M | 74.33M |
| Selling, General & Admin | 105.45M | 156.19M | 169.61M | 188.2M | 123.65M |
| Operating Expenses | 110.55M | 153.22M | 222.56M | 257.4M | 197.97M |
| Depreciation & Amortization | 70.4M | 83.2M | 92.98M | 101.62M | 95.55M |
| EBITDA | 316.63M | (57.61M) | 24.13M | (80.66M) | (13.89M) |
| EBITDA Margin | 51.2% | -7.7% | 3.1% | -10.1% | -1.8% |
| Operating Income | 41M | 20.85M | (47.51M) | (142.52M) | (135.31M) |
| Operating Margin | 6.6% | 2.8% | -6.1% | -17.9% | -17.9% |
| Interest Income | 2.27M | 8.34M | 9.26M | 2.44M | 4.25M |
| Interest Expense | 9.25M | 13.15M | 11.74M | 11.7M | 13.87M |
| Other Income / Expenses | 195.98M | (174.81M) | (33.09M) | (51.46M) | 12M |
| Income Before Tax | 236.98M | (153.96M) | (80.59M) | (193.98M) | (123.31M) |
| Pre-Tax Margin | 38.3% | -20.5% | -10.3% | -24.3% | -16.3% |
| Income Tax Expense | 21.47M | 21.7M | 3.32M | 2.1M | (23.88M) |
| Net Income | 215.51M | (175.66M) | (83.91M) | (196.08M) | (99.43M) |
| Net Margin | 34.9% | -23.4% | -10.7% | -24.6% | -13.1% |
| EPS (Basic) | 0.65 | (0.49) | (0.23) | (0.56) | (0.28) |
| EPS (Diluted) | 0.65 | (0.49) | (0.23) | (0.56) | (0.28) |
| Weighted Avg Shares | 332.81M | 353.35M | 353.87M | 353.29M | 355.16M |
| Weighted Avg Shares (Diluted) | 332.81M | 353.41M | 353.87M | 354.59M | 355.16M |
Evotec SE
NASDAQ:EVO
Intrinsic Alpha fair value
Locked
Current Price
$1.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.